Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 35NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 52Neoplasm Metastasis 41Multiple Myeloma 40Lymphoma 40Lung Neoplasms 38Breast Neoplasms 37Prostatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 31Leukemia, Myeloid, Acute 30Melanoma 27Colorectal Neoplasms 27Ovarian Neoplasms 26Urinary Bladder Neoplasms 22Pancreatic Neoplasms 22Hematologic Neoplasms 22Lymphoma, Non-Hodgkin 21Glioma 21Carcinoma, Renal Cell 20Sarcoma 18Myelodysplastic Syndromes 16Burkitt Lymphoma 16Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Neuroblastoma 14Colonic Neoplasms 14Brain Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 13Fallopian Tube Neoplasms 13

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Parkinson Disease 4, Autosomal Dominant Lewy Body × 30 days × Clear all
NCT03076554 2026-05-29

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
56 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡